Frost & Sullivan Publishes Quarterly Update on Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) - Oramed has a sufficient cash balance to fund its clinical development timeline in the near term; several clinical milestones are scheduled for 2018 and 2019; stock target price remains at NIS 53.2

Wednesday, May 9, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

Equity Research is published in the framework of the Tel Aviv Stock Exchange (TASE) Analysis Program

TEL AVIV, Israel, May 9, 2018 /PRNewswire/ -- The TASE analysis project was launched in 2016 in order to raise investors'

awareness to TASE listed technology and life-science companies and the markets in which these companies operate, thus creating appropriate pricing and increasing the exposure of investors from Israel and abroad. Its goal is to encourage investments in these companies by improving understanding of these industries and companies in the market.

In order to maintain professional, independent and unbiased analysis, the companies signed an agreement with the TASE to receive the analysis services for an obligatory period of two years. The companies cannot withdraw from the project during this period. The analysis is funded by the companies surveyed with funding from the Chief Scientist and the TASE.

Summary of Highlights

Oramed released its quarterly report for the period ending 28 February 2018 on 9 April, 2018 detailing the following:

A strong financial position with sufficient capital to fund scheduled clinical trials and associated expenses.

  • As of 28 February 2018, Oramed has capital resources of approx. $38.0M, enough to support 2018 clinical and regulatory plan.

Revenues from licensing deals with no cost of revenues have partially offset heavy R&D expenses to reduce Oramed's burn rate ahead of critical clinical milestones.

  • Revenues for the quarter ending February 28, 2018 totaled $604,000, consistent with $611,000 for the corresponding quarter in 2017.
  • Research and development expenses for the quarter ending February 28, 2018 decreased by 13% to $2,724,000, from $3,125,000 for the corresponding quarter in 2017.
  • Net losses for the quarter ending February 28, 2018 decreased by 8.4% to $2,916,000 from $3,183,000 for the corresponding period in 2017.

We maintain our valuation as per our Initiation of coverage report of 23 December 2017. Oramed's estimated equity value remains $200.7M / NIS 708.3M corresponding to a target price ranging between NIS 49.8 and NIS 56.6; a mean of NIS 53.2.

  • Three critical clinical milestones are expected for 2018, which justify the above valuation.
  • Three minor clinical milestones set for 2018 are promising indicators of a long-term expansion of Oramed's pharmaceutical portfolio, in terms of both more products, and more target indications.

About the company -  Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) (hereinafter 'Oramed') is a biomedical company engaged in pharmaceutical research and development of protein and peptide molecules, that are currently only available by injection. The company's initial pipeline targets the diabetes care market. The company advances two independent clinical programs that target the diabetes market; ORMD-0801-an oral insulin product, which aims to disrupt the treatment paradigm for type 2 diabetes, and decrease the number of insulin injections needed for type 1 diabetes; and ORMD-0901- an oral GLP-1 receptor agonist, which increases physiological insulin secretion.

Read the full report here.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us:  Start the discussion


Kristi CekaniCorporate Communications - Frost & Sullivan, EuropeP: +39.02.4851.6133E: kristi.cekani@frost.com


Cision View original content:

SOURCE Frost & Sullivan

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store